Sections

Heart Failure

Workup

Approach Considerations

Careful evaluation of the patient's history and physical examination (including signs of congestion, such as jugular venous distention) can provide important information about the underlying cardiac abnormality in heart failure (HF).^[3]However, other studies and/or tests may be necessary to identify structural abnormalities or conditions that can lead to or exacerbate HF.^[3]

Endomyocardial biopsy is indicated only when a specific diagnosis is suspected that would influence therapy in patients presenting with HF (see the image below).

Heart Failure. Transesophageal echocardiogram with continuous wave Doppler interrogation across the mitral valve. An increased mean gradient of 16 mmHg is revealed, consistent with severe mitral stenosis.

View Media Gallery

2022 ACC/AHA/HFSA guidelines

The American College of Cardiology, American Heart Association, and Heart Failure Society of America (ACC/AHA/HFSA) guidelines recommend the following for the diagnosis of HF^[4]:

Levels of: B-type natriuretic peptide/N-terminal BNP (BNP/NT-proBNP), urea and electrolytes, fasting glucose and HbA1c, lipids
12-Lead electrocardiography (ECG)
Transthoracic echocardiography (TTE)
Chest radiography
Complete blood cell (CBC) count
Thyroid function tests
Iron studies (transferrin saturation and ferritin)

Cardiac magnetic resonance imaging (CMRI) is recommended for the following^[4]:

Evaluation of myocardial structure and function in patients with poor echocardiogram acoustic windows
Characterization of myocardial in suspected infiltrative disease, Fabry disease, myocarditis, noncompacted left ventricle (LV), amyloid, sarcoidosis, iron overload/hemochromatosis

In patients with angina despite pharmacotherapy or who have symptomatic ventricular arrhythmias, invasive coronary angiography is recommended.

For those being evaluated for heart transplantation or mechanical circulatory support (MCS), cardiopulmonary exercise testing is recommended; in those with severe HF undergoing the evaluation for heart transplantation or MCS, right heart catheterization is recommended.

2021 ESC guidelines

The European Society of Cardiology (ESC) recommendations on the diagnosis of HF include the following^[68]:

HFpEF (heart failure with preserved ejection fraction) diagnosis requires evidence of cardiac structural or functional abnormalities as well as elevated plasma NP (natriuretic peptide) concentrations consistent with LV diastolic dysfunction and increased LV filling pressures. A diastolic stress test is recommended if these markers are equivocal.
A chest x-ray is recommended to identify other potential causes of breathlessness, such as pulmonary disease.
If the patient has a normal ECG, the diagnosis of HF is unlikely. The ECG may reveal abnormalities such as AF, Q waves, LV hypertrophy (LVH), and a widened QRS complex, which increase the likelihood of HF.
Basic tests such as serum urea and electrolytes, creatinine, full blood count, and liver and thyroid function tests are recommended to differentiate HF from other conditions, to provide prognostic information, and to guide potential therapy.
Echocardiography is recommended as the key investigative tool to assess cardiac function and provide information on other parameters such as chamber size, eccentric or concentric LVH, regional wall motion abnormalities, RV function, pulmonary hypertension, valvular function, and markers of diastolic function.

Routine Laboratory Tests

Laboratory studies should include a complete blood cell (CBC) count, serum electrolyte levels (including calcium and magnesium), and renal and liver function studies. Other tests may be indicated in specific patients. The CBC aids in the assessment of severe anemia, which may cause or aggravate heart failure.^{[69, 70]}Leukocytosis may signal underlying infection. Otherwise, CBCs are usually of little diagnostic help.

An assessment for iron deficiency should be considered; about one third of heart failure patients are also iron deficient, which is associated with poor cardiac function and can worsen outcomes in these individuals.^{[71, 72, 73]} Iron deficiency appears to impair contractility of human cardiomyocytes by impairing mitochondrial respiration and reducing contractility and relaxation; these effects can be reversed by restoring intracellular iron levels.^[72]

In a study that sought to define biomarker-based iron deficiency in heart failure based on bone marrow iron staining as the gold standard, as well as evaluate the prognostic value of the optimized definition, investigators found that a transferrin saturation (TSAT) up to 19.8% or a serum iron level up to 13 μmol/L had the best results in selecting patients with iron deficiency as well as identifying heart patients with the greatest mortality risk.^[70] These TSAT and serum iron values not only achieved a 94% sensitivity, and a respective 84% and 88% specificity (ie, specificity of 84% for TSAT ≤19.8% and 88% for serum iron ≤13 μmol/L), but both measures were also independent prognostic factors for mortality.^[70]

Serum electrolyte values are generally within reference ranges in patients with mild to moderate heart failure before treatment. In cases of severe heart failure, however, prolonged, rigid sodium restriction, coupled with intensive diuretic therapy and the inability to excrete water, may lead to dilutional hyponatremia, which occurs because of a substantial expansion of extracellular and intravascular fluid volume and a normal or increased level of total body sodium.

Potassium levels are usually within reference ranges, although the prolonged administration of diuretics may result in hypokalemia. Hyperkalemia may occur in patients with severe heart failure who show marked reductions in glomerular filtration rate (GFR) and inadequate delivery of sodium to the distal tubular sodium-potassium exchange sites of the kidney, particularly if they are receiving potassium-sparing diuretics and/or angiotensin-converting enzyme inhibitors (ACEIs).

Pulmonary function testing is generally not helpful in the diagnosis of heart failure. However, such testing may demonstrate or exclude respiratory causes of dyspnea and help in the assessment of any pulmonary causes of dyspnea.

Renal function tests

Blood urea nitrogen (BUN) and creatinine levels can be within reference ranges in patients with mild to moderate heart failure and normal renal function, although BUN levels and BUN/creatinine ratios may be elevated.

Patients with severe heart failure, particularly those on large doses of diuretics for long periods, may have elevated BUN and creatinine levels indicative of renal insufficiency owing to chronic reductions of renal blood flow from reduced cardiac output. Diuresing this group of patients is complex. In some individuals, diuretics will improve renal congestion and renal function, whereas in others, overaggressive diuresis may aggravate renal insufficiency due to volume depletion.

Liver function tests

Congestive hepatomegaly and cardiac cirrhosis are often associated with impaired hepatic function, which is characterized by abnormal values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactic dehydrogenase (LDH), and other liver enzymes. Hyperbilirubinemia secondary to an increase in the directly and indirectly reacting bilirubin is common. In severe cases of acute right ventricular (RV) or left ventricular (LV) failure, frank jaundice may occur.

Acute hepatic venous congestion can result in severe jaundice, with a bilirubin level as high as 15-20 mg/dL, elevation of AST to more than 10 times the upper reference range limit, elevation of the serum alkaline phosphatase level, and prolongation of the prothrombin time. The clinical and laboratory pictures may resemble viral hepatitis, but the impairment of hepatic function is rapidly resolved by successful treatment of heart failure. In patients with long-standing heart failure, albumin synthesis may be impaired, leading to hypoalbuminemia and intensifying the accumulation of fluid. Fulminant hepatic failure is an uncommon, late, and sometimes terminal complication of cardiac cirrhosis.

Natriuretic Peptides

Clinical findings and routine diagnostic tests are not always sufficient to diagnose heart failure. In such ambiguous cases, rapid measurement of B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) levels can aid clinicians in differentiating between cardiac and noncardiac causes of dyspnea.^{[3, 4, 8, 9, 65, 66, 74, 75]}That is, BNP is mostly limited to the differentiation of heart failure versus other causes of dyspnea in patients with an atypical presentation.

BNP is a 32-amino-acid polypeptide containing a 17-amino-acid ring structure common to all natriuretic peptides. The major source of plasma BNP is the cardiac ventricles, and the release of BNP appears to be in direct proportion to ventricular volume and pressure overload. BNP is an independent predictor of high LV end-diastolic pressure, and it is more useful than atrial natriuretic peptide (ANP) or norepinephrine levels for assessing mortality risk in patients with heart failure.^{[76, 77, 78, 79]}

Although BNP has been determined to be the strongest predictor of systolic versus nonsystolic heart failure (followed by oxygen saturation, history of myocardial infarction, and heart rate), BNP does not reliably differentiate between heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.^[74]Increased NT-proBNP was found to be the strongest independent predictor of a final diagnosis of acute heart failure.^{[80, 81, 82]}

Measurement of BNP and its precursor NT-proBNP in the urgent care setting can be used to establish the diagnosis of heart failure when the clinical presentation is ambiguous or when confounding comorbidities are present.^{[3, 8, 9]}BNP and NT-proBNP assays have different cutoff values for ruling in and ruling out heart failure.^{[61, 63, 83, 84, 85]}

BNP levels correlate closely with the New York Heart Association (NYHA) classification of heart failure.^{[86, 87]}BNP levels greater than 100 pg/mL have a specificity greater than 95% and a sensitivity greater than 98% when comparing patients without heart failure to all patients with heart failure.^[88]Even BNP levels greater than 80 pg/mL have a specificity greater than 95% and a sensitivity greater than 98% in the diagnosis of heart failure.^[83]

Table of cutoff values

Table 2, below, summarizes the evidence-based cutoff values of BNP and NT-proBNP for ruling in and ruling out the diagnosis of heart failure in the dyspneic patient presenting to the emergency department.

Table 2. Evidence-Based BNP and NT-proBNP Cutoff Values for Diagnosing HF (Open Table in a new window)

Criterion		BNP, pg/mL		NT-proBNP, pg/mL
Criterion		HF Unlikely (LR-Negative)	HF Likely (LR-Positive)	HF Unlikely (LR-Negative)	HF Likely (LR-Positive)
Age, y	>17	< 100 (0.13)^*	>500 (8.1)^*	-	-
	>21	-	-	< 300 (0.02)^†	-
	21-50	-	-	-	>450 (14)^†
	50-75	-	-	-	>900 (5.0)^†
	>75	-	-	-	>1800 (3.1)^†
Estimated GFR, < 60 mL/min		< 200 (0.13)^‡	>500 (9.3)^‡	-	-
BNP = B-type natriuretic peptide; GRF = glomerular filtration rate; HF = heart failure; LR = likelihood ratio; NPV = negative predictive value; NT-pro-BNP = N-terminal proBNP; PPV = positive predictive value; – = not specifically defined. ^* Derived from Breathing Not Properly data (1586 emergency department [ED] patients, prevalence of HF = 47%).^[65] ^† Derived from PRIDE data (1256 ED patients, prevalence of HF = 57%).^{[66, 75]} ^‡ Derived from subset of Breathing Not Properly data (452 ED patients, prevalence of HF = 49%).^[74]

BNP and NT-proBNP levels are higher in older patients,^[89]women,^[89]and patients with renal dysfunction^[90]or sepsis. Atrial fibrillation has also been associated with increased BNP levels in the absence of acute heart failure. However, BNP levels may be disproportionately lower in patients who are obese due to fat metabolism or who have hypothyroidism or advanced end-stage heart failure (the latter due to increased fibrosis). NT-proBNP plasma levels are also lower in obese heart failure patients relative to nonobese patients with heart failure, regardless of whether the etiology is ischemic or nonischaemic.^[91]

However, NT-proBNP may be elevated in severely obese patients (BMI >40 kg/m²) owing to an increased cardiac burden in these individuals.^[92]NT-pro-BNP may be a better marker for detecting cardiac dysfunction than BNP, because its chemical stability is better in circulating blood than that of BNP, and it is a sensitive marker of cardiac function even in early cardiac decompensation.^[93]

BNP measurement not indicated with nesiritide therapy

Nesiritide is a synthetic BNP analogue; therefore, the measurement of BNP is not indicated in patients who are receiving nesiritide. If BNP is used as a diagnostic marker to rule in heart failure, the level must be determined before nesiritide therapy is started.^{[94, 95, 96, 97]}

In a study by Miller et al, levels of NT-proBNP and BNP decreased in patients with advanced heart failure after therapy with nesiritide, but the majority of the patients did not have biochemically significant decreases in these markers even with a clinical response.^[98]The investigators were unable to give a definitive reason for their results, and they indicated that nesiritide therapy should not be guided by the use of levels of both markers.^[98]Fitzgerald et al also found decreased levels of both natriuretic peptides following nesiritide therapy in patients with decompensated heart failure.^[99]

For more information, see the Medscape Drugs & Diseases article Natriuretic Peptides in Congestive Heart Failure.

Genetic Testing

Cardiomyopathy phenotypes that have known genetic cause(s) include hypertrophic (HCM), dilated (DCM), restrictive (RCM), arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), and left ventricular noncompaction (LVNC). Because most cases of cardiomyopathy are treatable—which is not the case in many genetic diseases—and screening for genetic risk of cardiomyopathy before the onset of disease can guide the recommendations for early detection of disease and therapy (see Presentation, History),^{[9, 34]}it is recommended that consideration be given for patients with cardiomyopathy to be referred to centers with expertise in these matters and in family-based management.^[9]These specialized centers will have a better understanding of the complexities involved in genetic evaluation, testing, and counseling of patients with cardiomyopathy.

To establish specific gene testing and laboratories offering tests, please see GeneReviews for further information and larger reviews.

Genetic testing has the highest yield in three types of cardiomyopathy: DCM, HCM, and autosomal dominant ARVD/C. The diagnosis must be established using the specific criteria for each type of cardiomyopathy, as the genetic testing is different for each type.

Dilated cardiomyopathy

It is thought that approximately 20-50% of idiopathic dilated cardiomyopathy (IDC) may have a genetic basis. Screening first-degree relatives of a proband with IDC by echocardiography and electrocardiography (ECG) reveals that 20-48% of probands have affected relatives, consistent with a diagnosis of familial dilated cardiomyopathy (FDC).^{[100, 101, 102]}

Molecular genetic testing of the proband for an LMNA mutation is probably indicated, particularly if significant conduction system disease is present in the family. It should be noted that although the analytical sensitivity for detecting LMNA gene mutations is quite high, the clinical sensitivity (likelihood of identifying a mutation in a person with the disorder) is approximately 8% for FDC. Because molecular genetic testing for MYH7 has comparable clinical sensitivity, testing for mutations in MHY7 may also be considered.

Hypertrophic cardiomyopathy

HCM, caused by mutation in one of the genes currently known to encode different components of the sarcomere, is characterized by left ventricular (LV) hypertrophy (LVH) in the absence of predisposing cardiac conditions (eg, aortic stenosis) or cardiovascular conditions (eg, long-standing hypertension). Most often, the LVH of HCM becomes apparent during adolescence or young adulthood, although it may also develop late in life, in infancy, or in childhood.

Molecular genetic testing of any of the 14 genes currently known to encode different components of the sarcomere is clinically available. A detailed 3- to 4-generation family history should be obtained from relatives to assess the possibility of familial HCM. Attention should be directed to a history of any of the following in relatives: heart failure, HCM, cardiac transplantation, unexplained sudden death, unexplained cardiac conduction system disease and/or arrhythmia, or unexplained stroke or other thromboembolic disease.

Autosomal dominant arrhythmogenic right ventricular dysplasia/cardiomyopathy

ARVD/C is characterized by progressive fibrofatty replacement of the myocardium that predisposes to ventricular tachycardia and sudden death in young individuals and athletes. It primarily affects the RV; with time, it may also involve the LV. The presentation of disease is highly variable even within families, and affected individuals may not meet the established clinical criteria. The mean age at diagnosis is 31 years (±13 y; range, 4-64 y).

Genetic testing should be considered in individuals who have a clinical diagnosis of ARVD based on the diagnostic criteria. A case can be made to offer genetic testing to all with a clinical diagnosis of ARVD with a negative family history based on the high rate of reduced penetrance thus far identified with the ARVD genes. Molecular genetic testing is available on a clinical basis for TGFB3, RYR2, TMEM43, DSP, PKP2, DSG2, DSC2, and JUP.^[103]

For more information regarding genetic testing and cardiomyopathy, please see HFSA Guideline Approach to Medical Evidence for Genetic Evaluation of Cardiomyopathy, as well as Murphy RT, Starling RC. Genetics and cardiomyopathy: where are we now? Cleve Clin J Med. Jun 2005;72(6):465-6, 469-70, 472-3 passim.^[34]

Arterial and venous blood gases

Although arterial blood gas (ABG) measurement is more accurate than pulse oximetry for measuring oxygen saturation, it is unclear if ABG results add any clinical utility to pulse oximetry. In the setting of acute heart failure, ABG measurement is rarely performed. Indications include severe respiratory distress, documented hypoxemia by pulse oximetry not responsive to supplemental oxygen, and evidence of acidosis by serum chemistry findings or elevated lactate levels.

In general, heart failure patients who do not have comorbid lung disease do not manifest hypoxemia except in severe acute decompensation. Patients with severe heart failure may have signs and symptoms ranging from severe hypoxemia, or even hypoxia, along with hypercapnia, to decreased vital capacity and poor ventilation.

ABG measurement helps assess the presence of hypercapnia, a potential early marker for impending respiratory failure. Hypoxemia and hypocapnia occur in stages 1 and 2 of pulmonary edema because of a ventilation/perfusion (V/Q) mismatch. In stage 3 of pulmonary edema, right-to-left intrapulmonary shunt develops secondary to alveolar flooding and further contributes to hypoxemia. In more severe cases, hypercapnia and respiratory acidosis are usually observed. The decision regarding intubation and the use of mechanical ventilation is frequently based on many clinical parameters, including oxygenation, ventilation, and mental status. ABG values in isolation are rarely useful, but they may add to the entire clinical picture.

Mixed venous oxygen saturation (obtained from the main pulmonary artery in the absence of an intracardiac shunt) is a good marker of the blood circulation time and thus of the cardiac output and cardiac performance. Patients who have advanced heart failure have low cardiac output and slower circulation time, which translate into an increased oxygen extraction by the tissues and therefore lower oxygen (< 60% saturation).

Pulse oximetry

Pulse oximetry is highly accurate at assessing the presence of hypoxemia and, therefore, the severity of acute heart failure presentations. Patients with mild to moderate acute heart failure may show modest reductions in oxygen saturation, whereas patients with severe heart failure may have severe oxygen desaturation, even at rest. Pulse oximetry is also useful for monitoring the patient's response to supplemental oxygen and other therapies.

Patients with mild to moderate heart failure may have normal oxygen saturations at rest, but they may exhibit marked reductions in oxygen saturations during physical exertion or recumbency. In general, arterial desaturation during exercise is not expected in heart failure and suggests the presence of comorbid lung disease. The use of continuous oxygen may be needed until compensation returns oxygen saturation to normal during exertion and recumbency or on a permanent basis if oxygen desaturation during exertion and/or recumbency exists during compensated severe chronic heart failure.

Electrocardiography

A screening electrocardiogram (ECG) is reasonable in patients with symptoms suggestive of heart failure. The presence of left atrial enlargement and left ventricular (LV) hypertrophy (LVH) is sensitive (although nonspecific) for chronic LV dysfunction. It is unlikely that an ECG would be completely normal in the presence of heart failure; therefore, an alternative diagnosis should be sought in such cases.^{[8, 9]}

Electrocardiography may suggest an acute tachyarrhythmia or bradyarrhythmia as the cause of heart failure. It may also aid in the diagnosis of acute myocardial ischemia or infarction as the cause of heart failure, or it may suggest the likelihood of a prior myocardial infarction or the presence of coronary artery disease as the cause of heart failure.^{[3, 9]}

Heart failure can have multiple and diverse presentations on ECGs (see the images below).

Heart Failure. This electrocardiogram (ECG) is from a 32-year-old female with recent-onset congestive heart failure and syncope. The ECG demonstrates a tachycardia with a 1:1 atrial:ventricular relationship. It is not clear from this tracing whether the atria are driving the ventricles (sinus tachycardia) or the ventricles are driving the atria (ventricular tachycardia [VT]). At first glance, sinus tachycardia in this ECG might be considered with severe conduction disease manifesting as marked first-degree atrioventricular block with left bundle branch block. On closer examination, the ECG morphology gives clues to the actual diagnosis of VT. These clues include the absence of RS complexes in the precordial leads, a QS pattern in V6, and an R wave in aVR. The patient proved to have an incessant VT associated with dilated cardiomyopathy.

View Media Gallery

Heart Failure. Electrocardiogram depicting ventricular fibrillation in a patient with a left ventricular assist device (LVAD). Ventricular fibrillation is often due to ischemic heart disease and can lead to myocardial infarction and/or sudden death.

View Media Gallery

Heart Failure. This electrocardiogram (ECG) shows evidence of severe left ventricular hypertrophy (LVH) with prominent precordial voltage, left atrial abnormality, lateral ST-T abnormalities, and a somewhat leftward QRS axis (–15º). The patient had malignant hypertension with acute heart failure, accounting also for the sinus tachycardia (blood pressure initially 280/180 mmHg). The ST-T changes seen here are nonspecific and could be due to, for example, LVH alone or coronary artery disease. However, the ECG is not consistent with extensive inferolateral myocardial infarction. Image courtesy of http://ecg.bidmc.harvard.edu.

View Media Gallery

Heart Failure. This electrocardiogram shows an extensive acute/evolving anterolateral myocardial infarction pattern, with ST-T changes most apparent in leads V2-V6, I, and aVL. Slow R-wave progression is also present in leads V1-V3. The rhythm is borderline sinus tachycardia with a single premature atrial complex (PAC) (fourth beat). Note also the low limb-lead voltage and probable left atrial abnormality. Left ventriculography showed diffuse hypokinesis as well as akinesis of the anterolateral and apical walls, with an ejection fraction estimated at 33%. Image courtesy of http://ecg.bidmc.harvard.edu.

View Media Gallery

Heart Failure. This electrocardiogram shows a patient is having an evolving anteroseptal myocardial infarction secondary to cocaine. There are Q waves in leads V2-V3 with ST-segment elevation in leads V2-V5 associated with T-wave inversion. Also noted are biphasic T waves in the inferior leads. These multiple abnormalities suggest occlusion of a large left anterior descending artery that wraps around the apex of the heart (or multivessel coronary artery disease). Image courtesy of http://ecg.bidmc.harvard.edu.

View Media Gallery

Electrocardiography is of limited help when an acute valvular abnormality or LV systolic dysfunction is considered to be the cause of heart failure; however, the presence of left bundle branch block (LBBB) on an ECG is a strong marker for diminished LV systolic function.

Chest Radiography

Chest radiographs (see the images below) are used in cases of heart failure to assess heart size, pulmonary congestion, pulmonary or thoracic causes of dyspnea, and the proper positioning of any implanted cardiac devices.^{[3, 8, 9]} Posterior-anterior and lateral views are recommended.^[9]

Heart Failure. This chest radiograph shows an enlarged cardiac silhouette and edema at the lung bases, signs of acute heart failure.

View Media Gallery

Heart Failure. A 28-year-old woman presented with acute heart failure secondary to chronic hypertension. The enlarged cardiac silhouette on this anteroposterior (AP) radiograph is caused by acute heart failure due to the effects of chronic high blood pressure on the left ventricle. The heart then becomes enlarged, and fluid accumulates in the lungs (ie, pulmonary congestion).

View Media Gallery

Although up to 50% of patients with heart failure and documented elevation of pulmonary capillary wedge pressure (PCWP) do not manifest typical radiographic findings of pulmonary congestion, two principal features of chest radiographs are useful in the evaluation of patients with heart failure: (1) the size and shape of the cardiac silhouette and (2) edema at the lung bases.

Echocardiography

Two-dimensional (2-D) echocardiography is recommended in the initial evaluation of patients with known or suspected heart failure.^{[3, 8, 9]}Ventricular function may be evaluated, and primary and secondary valvular abnormalities may be accurately assessed.^{[104, 105, 106, 107, 108, 109]}

Doppler echocardiography, along with 2-D echocardiography, may play a valuable role in determining diastolic function and in establishing the diagnosis of diastolic heart failure. Approximately 30-40% of patients presenting with heart failure have normal systolic function but abnormal diastolic relaxation. The primary finding to differentiate diastolic heart failure is the presence of a normal ejection fraction; however, note that findings of diastolic dysfunction are common in the elderly and may not be associated with clinical heart failure. Because the therapy for this condition is distinctly different from that for systolic dysfunction, establishing the appropriate etiology and diagnosis is essential.

Doppler and 2-D echocardiography may also be used to determine both systolic and diastolic left ventricular (LV) performance, cardiac output (ejection fraction), and pulmonary artery and ventricular filling pressures. In addition, echocardiography may be used to identify clinically important valvular disease (see the images below).

Heart Failure. Cervicocephalic fibromuscular dysplasia (FMD) can lead to complications such as hypertension and chronic kidney failure, which can lead to heart failure. In this color Doppler and spectral Doppler ultrasonographic examination of the left internal carotid artery (ICA) in a patient with cervicocephalic FMD, stenoses of about 70% is seen in the ICA.

View Media Gallery

Heart Failure. Cervicocephalic fibromuscular dysplasia (FMD) can lead to complications such as hypertension and chronic kidney failure, which, in turn, can lead to heart failure. Nodularity in an artery is known as the "string-of-beads sign," and it can be seen this color Doppler ultrasonographic image from a 51-year-old patient with low-grade stenosing FMD of the internal carotid artery (ICA).

View Media Gallery

Heart Failure. Echocardiogram of a patient with severe pulmonic stenosis. This image shows a parasternal short-axis view of a thickened pulmonary valve. Pulmonic stenosis can lead to pulmonary hypertension, which can result in hepatic congestion and in right-sided heart failure.

View Media Gallery

Heart Failure. This video is an echocardiogram of a patient with severe pulmonic stenosis. The first segment shows the parasternal short-axis view of the thickened pulmonary valve. The second segment shows the presence of moderate pulmonary insufficiency (orange color flow). AV = aortic valve, PA = pulmonary artery, PI = pulmonary insufficiency, PV = pulmonary valve.

View Media Gallery

The following video is from a patient with arrhythmogenic right ventricular dysplasia (ARVD), a congenital cardiomyopathy that can lead to heart failure.

Heart Failure. Apical four-chamber echocardiogram in a 37-year-old man with arrhythmogenic right ventricular dysplasia (ARVD), a congenital cardiomyopathy. Note the prominent trabeculae and abnormal wall motion of the dilated RV. ARVD can result in ventricular and supraventricular arrhythmias. The most significant of all rhythms associated with heart failure are the life-threatening ventricular arrhythmias.

View Media Gallery

Transesophageal echocardiography

Transesophageal echocardiography (TEE) is particularly useful in patients who are on mechanical ventilation or are morbidly obese and in patients whose transthoracic echocardiogram is suboptimal in its imaging.^{[8, 110]}It is an easy and safe alternative to conventional transthoracic echocardiography (TTE) and provides better imaging quality (see the following video). Transesophageal echocardiography also has the potential to be a noninvasive alternative to pulmonary artery catherization (Swan-Gantz catheterization) for hemodynamic monitoring, as it also allows the measurement of central venous, pulmonary arterial, and pulmonary capillary wedge pressures, as well as pulmonary and systemic vascular resistance, and stroke volume and cardiac output.^[110]

Heart Failure. This transthoracic echocardiogram demonstrates severe mitral regurgitation with a heavily calcified mitral valve and prolapse of the posterior leaflet into the left atrium.

View Media Gallery

Stress echocardiography

Stress echocardiography, also known as dobutamine or exercise echocardiography, has several uses; however, in heart failure, this technique is used mainly to assess coronary artery disease. This imaging modality may be used to detect ventricular dysfunction caused by ischemia, evaluate myocardial viability in the presence of marked hypokinesis or akinesis, identify myocardial stunning and hibernation, and relate heart failure symptoms to valvular abnormalities.^[8]However, stress echocardiography may have a lower sensitivity and specificity in heart failure patients because of LV dilatation or because of the presence of bundle branch block.

CT Scanning and MRI

Computed tomography (CT) scanning or magnetic resonance imaging (MRI) may be useful in evaluating cardiac chamber size and ventricular mass, cardiac function, and wall motion; delineating congenital and valvular abnormalities; and demonstrating the presence of pericardial disease.^[3]However, cardiac CT scanning is usually not required in the routine diagnosis and management of heart failure, and echocardiography and MRI may provide similar information without exposing the patient to ionizing radiation.

The benefits of cardiac MRI (cMRI) include the ability to obtain a great deal of information with a noninvasive test. This modality provides detailed functional and morphologic information; can be used to assess ischemic versus nonischemic disease, infiltrative disease, and hypertrophic disease; and can be employed to determine viability. It is used principally for the delineation of congenital cardiac abnormalities and for the assessment of valvular heart disease, and it is the gold standard for evaluating right ventricular (RV) function (see the video below).

Heart Failure. Cardiac magnetic resonance image (CMRI), short-axis view. This image shows right ventricular (RV) dilatation, trabucular derangement, aneurysm formation, and dyskinetic free wall in a patient with arrhythmogenic RV dysplasia.

View Media Gallery

MRI has become particularly useful for evaluating abnormalities in wall motion and viable myocardium, and MRI findings can help predict the success of revascularization in patients with low ejection fractions.^[111]However, the detailed information obtained by MRI must be balanced by its high costs and the fact that this imaging modality cannot be performed in patients with implantable defibrillators.

Radionuclide multiple-gated acquisition scanning

Radionuclide multiple-gated acquisition (MUGA) scan is a reliable imaging technique for the evaluation of left ventricular (LV) and right ventricular (RV) function and wall motion abnormalities. Because of its reliability, LV ejection fraction (LVEF), as determined by MUGA scanning, is often used for serial assessment of postchemotherapy LV function.^[112]

Electrocardiogram-gated myocardial perfusion imaging

The high photon flux of compounds labeled with technetium-99m (^99mTc) makes it feasible to acquire myocardial perfusion images in an electrocardiogram (ECG)-gated mode. ECG-gated single-photon emission computed tomography (SPECT) images allow for the assessment of the global LVEF, regional wall motion, and regional wall thickening at rest in patients with documented stress-induced wall motion and perfusion abnormalities.

In general, LVEF from gated SPECT scanning agrees well with resting LVEF determined by other modalities. Quality assurance is important, however, because determinations of LVEF with gated SPECT scanning may be less accurate, even invalidated, in the presence of an irregular heart rate, low count density, intense extracardiac radiotracer uptake adjacent to the LV, or a small LV.

Combined interpretation of perfusion and function on ECG-gated images substantially increases the confidence of the interpretation. Taillefer and associates reported that the interpretation of stress and rest end-diastolic section, rather than summed ungated sections, may enhance the overall sensitivity for the detection of mild coronary artery disease.^[113]

ECG-gated images are also useful for recognizing artifactual defects caused by attenuation (breast and diaphragm) and thus are useful in the quality control of SPECT imaging. ECG-gated SPECT imaging is considered state of the art of radionuclide myocardial perfusion imaging.

Three important practical issues need to be addressed in the evaluation of patients with presumed ischemic dysfunction, as follows:

Assessment of the relative regional myocardial uptake of thallium-201 ( ²⁰¹Tl; often after rest reinjection), ^99mTc-sestamibi, or ^99m Tc-tetrofosmin (often after rest administration of nitroglycerin); when the resting uptake of radiotracer is greater than 50% of normal, expect recovery of function after revascularization
Assessment of the presence of demonstrable ischemia (eg, partially reversible defect) in a myocardial segment with decreased uptake, even if the resting uptake is less than 50%
Data reported in 2011 from a STICH viability substudy failed to demonstrate a significant impact on survival based on the extent of the viable myocardium in patients with coronary artery disease and LV dysfunction treated surgically or medically ^[114]

Equilibrium radionuclide angiocardiography

Equilibrium radionuclide angiocardiography (ERNA) uses ECG events to define the temporal relationship between the acquisition of nuclear data and the volumetric components of the cardiac cycle. Sampling is performed repetitively over several hundred heartbeats, with physiologic segregation of the nuclear data in accordance with their occurrence within the cardiac cycle.

Data are quantified and displayed in an endless-loop, cinegraphic format for additional qualitative visual interpretation and analysis. Equilibrium blood-pool labeling is achieved by use of ^99mTc. Data are analyzed by use of a computer, generally with some operator interaction.

Analysis may be obtained in either the frame or list mode. Radionuclide data are collected and segregated temporally. The process generally requires 3-10 minutes for completion of each view. Following data acquisition, data from the several hundred individual beats are summed, processed, and displayed as a single representative cardiac cycle.

Data from the left anterior oblique (LAO) view are also used for qualitative analysis of global LV function. On this view, overlap of the two ventricles is minimal. In a count-based approach, LVEF and other indices of filling and ejection are calculated from the LV radioactivity preset at various points throughout the cardiac cycle.

Right ventricular (RV) function is best evaluated by first-pass techniques. The LAO view provides qualitative information concerning contraction of the septal, inferoapical, and lateral walls. The anterior view provides data concerning the regional motion of the anterior and apical segments. The left lateral or left posterior oblique view provides optimal qualitative information concerning contraction of the inferior wall and posterobasal segment.

ERNA may easily be combined with additional physiologic stress testing or provocation, which may be in the form of either physiologic stress, such as exercise; pharmacologic stress, with the use of positive inotropic agents, such as dobutamine or isoproterenol; or psychological stress. The degree of confidence with ERNA is moderately high. False-positive and false-negative findings are infrequent.

Radionuclide ventriculography

Radionuclide ventriculography is most often performed as part of a myocardial perfusion scan to obtain accurate measurements of LV function and RV ejection fraction (RVEF),^{[3, 8]} but it is unable to directly assess valvular abnormalities or cardiac hypertrophy and has limited value for assessing volumes or more subtle indices of systolic or diastolic function.

Iobenguane scanning for cardiac risk evaluation

The scintigraphic imaging agent iobenguane I 123 injection (AdreView) is used for the evaluation of myocardial sympathetic innervation in patients with New York Heart Association (NYHA) class 2-3 heart failure with an LVEF of 35% or less.^[10]This radionuclide tracer, which functions molecularly as a norepinephrine analogue, can show relative levels of norepinephrine uptake in the cardiac sympathetic nervous system and contribute to risk stratification in heart failure patients. Improved reuptake of norepinephrine is associated with a better prognosis.^[10]

Catheterization and Angiography

In patients with a nonischemic cardiomyopathy, perfusion deficits and segmental wall-motion abnormalities suggestive of coronary artery disease are commonly present on noninvasive imaging.^[3]Only coronary angiography, however, can reliably demonstrate or exclude the presence of obstructed coronary vessels (see the following image).^[3]

Heart Failure. A color-enhanced angiogram of the left heart shows a plaque-induced obstruction (top center) in a major artery, which can lead to myocardial infarction (MI). MIs can precipitate heart failure.

View Media Gallery

The procedures are frequently indicated when systolic dysfunction of unexplained cause is present on noninvasive testing or when normal systolic function with episodic heart failure suggests ischemically mediated left ventricular (LV) dysfunction. However, although coronary angiography may be indicated in young patients to exclude the presence of congenital coronary anomalies, this procedure may not be as useful in older patients, because revascularization has not been shown to improve clinical outcomes in patients without angina.^[3]Despite this, because revascularization may improve LV function, some experts suggest that coronary artery disease should be excluded whenever possible, especially in patients with diabetes mellitus or other states associated with silent myocardial ischemia.^[3]The degree of confidence is moderately high.

Right-sided heart catheterization

Right heart catheterization is useful in providing important hemodynamic information about filling pressures, vascular resistance, and cardiac output when there is doubt about the patient's fluid status; in heart failure refractory to initial therapy; in the presence of significant hypotension (systolic blood pressure typically < 90 mm Hg or symptomatic low systolic blood pressure) and/or worsening renal function during initial treatment; and when heart transplantation or placement of a mechanical circulatory support device is being considered.^[3]However, it plays a limited role in the diagnosis of heart failure, as studies evaluating right heart catheterization and overall improved outcomes have been essentially neutral.^[115]

Normal right-sided hemodynamics include a right atrial pressure less than 7 mm Hg, right ventricular (RV) pressure below 30/7 mm Hg, pulmonary pressure less than 30/18 mm Hg, pulmonary capillary wedge pressure (PCWP) below 18 mm Hg, and cardiac index (CI) above 2.2 L/min/m².

PCWP can be measured by using a pulmonary arterial catheter (Swan-Ganz catheter). This helps to differentiate cardiogenic causes of decompensated heart failure from noncardiogenic causes, such as acute respiratory distress syndrome (ARDS), which occurs secondary to injury to the alveolar-capillary membrane rather than to alteration in Starling forces. A PCWP exceeding 18 mm Hg in a patient not known to have chronically elevated left atrial pressure is indicative of cardiogenic decompensated heart failure. In patients with chronic pulmonary capillary hypertension, capillary wedge pressures exceeding 25 mm Hg are generally required to overcome the pumping capacity of the lymphatics and produce pulmonary edema.

Large V waves may be observed in the PCWP tracing in patients with significant mitral regurgitation because large volumes of blood regurgitate into a poorly compliant left atrium. This raises the pulmonary venous pressure and may cause pulmonary edema.

Left-sided heart catheterization

Left-sided heart catheterization and coronary angiography should be undertaken when the etiology of heart failure cannot be determined by clinical or noninvasive imaging methods or when the etiology is likely to be due to acute myocardial ischemia or infarction. Coronary angiography is particularly helpful in patients with LV systolic dysfunction and known or suspected coronary artery disease in whom myocardial ischemia is thought to play a dominant role in the reduction of LV systolic function and the worsening of heart failure.

Assessment of Functional Capacity

Cardiopulmonary stress testing (maximal exercise stress testing with measurement of respiratory gas exchange) can help in the assessment of a patient’s chance of survival within the next year, as well as determine the need for referral for either cardiac transplantation or implantation of mechanical circulatory support. A 6-minute walk test evaluates the distance walked, dyspnea index on a Borg scale from 0 to 10, oxygen saturation, and heart rate response to exercise. A normal value is walking more than 1500 feet. Patients who walk less than 600 feet have severe cardiac dysfunction and a worse short- and long-term prognosis.^[8]

Treatment & Management

Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct. 22(4 suppl A):6A-13A. [QxMD MEDLINE Link]. [Full Text].
American Heart Association. Classes of heart failure. Available at http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.WUcGf-vyuHs. Updated: May 8, 2017; Accessed: June 18, 2017.
[Guideline] Yancy CW, Jessup M, Bozkurt B, et al, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15. 128(16):e240-327. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May 3. 79 (17):e263-e421. [QxMD MEDLINE Link]. [Full Text].
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: executive summary: s report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3. 145 (18):e876-94. [QxMD MEDLINE Link]. [Full Text].
Stiles S. New HF guidelines feature 'quad' therapy, tweaked terminology. Medscape Medical News. Available at https://www.medscape.com/viewarticle/971492. April 3, 2022; Accessed: May 6, 2022.
Pina IL. Key points from the new heart failure guidelines [commentary]. TheHeart.org. Available at https://www.medscape.com/viewarticle/971949. May 4, 2022; Accessed: May 6, 2022.
[Guideline] Ponikowski P, Voors AA, Anker SD, et al, for the Authors/Task Force Members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14. 37(27):2129-200. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Lindenfeld J, Albert NM, Boehmer JP, et al, for the Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun. 16(6):e1-194. [QxMD MEDLINE Link]. [Full Text].
Stiles S. FDA approves heart sympathetic activity imaging agent for HF evaluation. Medscape News from WebMD. March 22, 2013. Available at http://www.medscape.com/viewarticle/781309. Accessed: April 5, 2013.
Braunwald E. The pathogenesis of congestive heart failure: then and now. Medicine. 1991 Jan. 70(1):68-79. [Full Text].
Braunwald E, Ross J Jr, Sonnenblick EH. Mechanisms of Contraction of the Normal and Failing Heart. 2nd ed. Boston: Little Brown & Co; 1976.
Greyson CR. Pathophysiology of right ventricular failure. Crit Care Med. 2008 Jan. 36(1 suppl):S57-65. [QxMD MEDLINE Link].
Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008 Apr 1. 117(13):1717-31. [QxMD MEDLINE Link].
Onwuanyi A, Taylor M. Acute decompensated heart failure: pathophysiology and treatment. Am J Cardiol. 2007 Mar 26. 99(6B):25D-30D. [QxMD MEDLINE Link].
Ross J Jr, Braunwald E. Studies on Starling's law of the heart. IX. The effects of impeding venous return on performance of the normal and failing human left ventricle. Circulation. 1964 Nov. 30:719-27. [QxMD MEDLINE Link]. [Full Text].
Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009 Feb 17. 53(7):557-73. [QxMD MEDLINE Link]. [Full Text].
Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A. 1998 Jul 21. 95(15):8801-5. [QxMD MEDLINE Link]. [Full Text].
Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995 May 15. 91(10):2504-7. [QxMD MEDLINE Link]. [Full Text].
Cody RJ. Hormonal alterations in heart failure. In: Hosenpud JB, Greenberg BH, eds. Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. 199-212.
Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. Nature. 2002 Jan 10. 415(6868):240-3. [QxMD MEDLINE Link].
Leri A, Claudio PP, Li Q, et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest. 1998 Apr 1. 101(7):1326-42. [QxMD MEDLINE Link]. [Full Text].
Kajstura J, Leri A, Castaldo C, Nadal-Ginard B, Anversa P. Myocyte growth in the failing heart. Surg Clin North Am. 2004 Feb. 84(1):161-77. [QxMD MEDLINE Link].
Henes J, Rosenberger P. Systolic heart failure: diagnosis and therapy. Curr Opin Anaesthesiol. 2016 Feb. 29(1):55-60. [QxMD MEDLINE Link].
Nicoara A, Jones-Haywood M. Diastolic heart failure: diagnosis and therapy. Curr Opin Anaesthesiol. 2016 Feb. 29(1):61-7. [QxMD MEDLINE Link].
Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000 Mar 1. 35(3):537-44. [QxMD MEDLINE Link]. [Full Text].
Gary R, Davis L. Diastolic heart failure. Heart Lung. 2008 Nov-Dec. 37(6):405-16. [QxMD MEDLINE Link].
Morris DA, Gailani M, Vaz Perez A, et al. Right ventricular myocardial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr. 2011 Aug. 24(8):886-97. [QxMD MEDLINE Link].
Jousilahti P, Harald K, Jula A, et al, for the National Institute for Health and Welfare-THL - Helsinki - Finland. Salt intake and the risk of heart failure [abstract 1192]. Presented at: European Society of Cardiology 2017 Congress; August 27, 2017; Barcelona, Spain. Eur Heart J. Aug 2017. 38(suppl 1):240. [Full Text].
Davenport L. High salt intake linked to increased heart-failure risk. Medscape News from WebMD. August 28, 2017. Available at http://www.medscape.com/viewarticle/884824. Accessed: September 1, 2017.
Lam CS, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation. 2011 Jul 5. 124(1):24-30. [QxMD MEDLINE Link]. [Full Text].
Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993 Jul. 88(1):107-15. [QxMD MEDLINE Link]. [Full Text].
Halley CM, Houghtaling PL, Khalil MK, Thomas JD, Jaber WA. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med. 2011 Jun 27. 171(12):1082-7. [QxMD MEDLINE Link]. [Full Text].
Murphy RT, Starling RC. Genetics and cardiomyopathy: where are we now?. Cleve Clin J Med. 2005 Jun. 72(6):465-6, 469-70, 472-3 passim. [QxMD MEDLINE Link].
Benjamin EJ, Blaha MJ, Chiuve SE, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017 Mar 7. 135(10):e146-e603. [QxMD MEDLINE Link]. [Full Text].
Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2000–2014. Centers for Disease Control and Prevention. December 31, 2015. Available at http://www.cdc.gov/nchs/data/databriefs/db231.htm. Accessed: January 5, 2016.
Brauser D. CDC: Heart-failure–related mortality rate climbs after decade-long decrease. Heartwire from Medscape. January 4, 2016. Available at http://www.medscape.com/viewarticle/856704. Accessed: January 5, 2016.
Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011 Oct 19. 306(15):1669-78. [QxMD MEDLINE Link]. [Full Text].
Kolte D, Abbott JD, Aronow HD. Interventional therapies for heart failure in older adults. Heart Fail Clin. 2017 Jul. 13(3):535-70. [QxMD MEDLINE Link].
Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin. 2017 Jul. 13(3):417-26. [QxMD MEDLINE Link].
Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009 Apr 2. 360(14):1418-28. [QxMD MEDLINE Link]. [Full Text].
Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation. 2008 Dec 2. 118(23):2360-7. [QxMD MEDLINE Link]. [Full Text].
Damasceno A, Cotter G, Dzudie A, Sliwa K, Mayosi BM. Heart failure in Sub-Saharan Africa: time for action. J Am Coll Cardiol. 2007 Oct 23. 50(17):1688-93. [QxMD MEDLINE Link]. [Full Text].
Mbewu A, Mbanya JC. Cardiovascular diseases. In: Jamison DT, Feachem RG, Makgoba MW, et al, eds. Disease and mortality in Sub-Saharan Africa. 2nd ed. Washington, DC: World Bank Publications; 2006. 305-28.
Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000 Mar 1. 35(3):681-9. [QxMD MEDLINE Link]. [Full Text].
Fonarow GC, Adams KF Jr, Abraham WT, et al, for the ADHERE Scientific Advisory Committee, Study Group and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005 Feb 2. 293(5):572-80. [QxMD MEDLINE Link]. [Full Text].
Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002 Oct 31. 347 (18):1397-402. [QxMD MEDLINE Link].
Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec. 140(6):840-7. [QxMD MEDLINE Link].
MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000 Sep 5. 102(10):1126-31. [QxMD MEDLINE Link]. [Full Text].
Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011 Sep-Oct. 54(2):86-96. [QxMD MEDLINE Link].
van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation. 2011 Jul 19. 124(3):289-96. [QxMD MEDLINE Link]. [Full Text].
Bursi F, McNallan SM, Redfield MM, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012 Jan 17. 59(3):222-31. [QxMD MEDLINE Link]. [Full Text].
Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012 Oct 2. 60(14):1249-56. [QxMD MEDLINE Link].
Nayar P, Yu F, Chandak A, Kan GL, Lowes B, Apenteng BA. Risk factors for in-hospital mortality in heart failure patients: does rurality, payer or admission source matter?. J Rural Health. 2018 Dec. 34(1):103-8. [QxMD MEDLINE Link].
Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc. 2011 Apr. 86(4):273-81. [QxMD MEDLINE Link]. [Full Text].
DeWalt DA, Schillinger D, Ruo B, et al. Multisite randomized trial of a single-session versus multisession literacy-sensitive self-care intervention for patients with heart failure. Circulation. 2012 Jun 12. 125 (23):2854-62. [QxMD MEDLINE Link].
Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail. 2007 Mar. 9(3):292-9. [QxMD MEDLINE Link].
Panjrath G, Ahmed A. Diagnosis and management of heart failure in older adults. Heart Fail Clin. 2017 Jul. 13(3):427-44. [QxMD MEDLINE Link].
Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989 Feb 10. 261(6):884-8. [QxMD MEDLINE Link].
Steinhart B, Thorpe KE, Bayoumi AM, Moe G, Januzzi JL Jr, Mazer CD. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol. 2009 Oct 13. 54(16):1515-21. [QxMD MEDLINE Link].
[Guideline] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8. 136(6):e137-e161. [QxMD MEDLINE Link]. [Full Text].
Rich MW, McSherry F, Williford WO, Yusuf S, for the Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001 Sep. 38(3):806-13. [QxMD MEDLINE Link].
[Guideline] Yancy CW, Jessup M, Bozkurt B, et al, for the Writing Committee Members. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016 Sep 27. 134(13):e282-93. [QxMD MEDLINE Link]. [Full Text].
Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011 Sep 6. 58(11):1152-61. [QxMD MEDLINE Link].
Maisel AS, Krishnaswamy P, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002 Jul 18. 347(3):161-7. [QxMD MEDLINE Link].
Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005 Apr 15. 95(8):948-54. [QxMD MEDLINE Link].
Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure?. JAMA. 2005 Oct 19. 294(15):1944-56. [QxMD MEDLINE Link].
[Guideline] McDonagh TA, Metra M, Adamo M, et al, for the ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21. 42(36):3599-726. [QxMD MEDLINE Link]. [Full Text].
Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008 Sep 2. 52(10):818-27. [QxMD MEDLINE Link].
Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant?. JACC Heart Fail. 2018 Mar. 6(3):201-8. [QxMD MEDLINE Link]. [Full Text].
Beedkar A, Parikh R, Deshmukh P. Heart failure and the iron deficiency. J Assoc Physicians India. 2017 Nov. 65(11):79-80. [QxMD MEDLINE Link].
Hoes MF, Grote Beverborg N, Kijlstra JD, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018 May. 20(5):910-9. [QxMD MEDLINE Link]. [Full Text].
Rocha BML, Cunha GJL, Menezes Falcao LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018 Feb 20. 71(7):782-93. [QxMD MEDLINE Link].
Maisel AS, McCord J, Nowak RM, et al, for the Breathing Not Properly Multinational Study Investigators. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003 Jun 4. 41(11):2010-7. [QxMD MEDLINE Link]. [Full Text].
Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb. 27(3):330-7. [QxMD MEDLINE Link].
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998 May. 135(5 Pt 1):825-32. [QxMD MEDLINE Link].
Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003 Aug. 89(8):879-81. [QxMD MEDLINE Link]. [Full Text].
Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994 May. 89(5):1934-42. [QxMD MEDLINE Link].
Andersson B, Hall C. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail. 2000 Sep. 6(3):208-13. [QxMD MEDLINE Link].
Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000 May. 2(3):198-205. [QxMD MEDLINE Link].
Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001 Feb. 37(2):386-91. [QxMD MEDLINE Link].
Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997 Nov 8. 350(9088):1349-53. [QxMD MEDLINE Link].
Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001 Feb. 37(2):379-85. [QxMD MEDLINE Link].
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998 May. 135(5 pt 1):825-32. [QxMD MEDLINE Link].
Maisel AS, Koon J, Hope J, et al. A rapid bedside test for brain natriuretic peptide accurately predicts cardiac function in patients referred for echocardiography. Am Heart J. 2001. 141:374-9.
Masson S, Vago T, Baldi G, et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Clin Chem Lab Med. 2002 Aug. 40(8):761-3. [QxMD MEDLINE Link].
Song BG, Jeon ES, Kim YH, et al. Correlation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failure. Korean J Intern Med. 2005 Mar. 20(1):26-32. [QxMD MEDLINE Link].
Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002 Jun 22. 324(7352):1498. [QxMD MEDLINE Link]. [Full Text].
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002 Sep 4. 40(5):976-82. [QxMD MEDLINE Link].
St Peter JV, Hartley GG, Murakami MM, Apple FS. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem. 2006 Apr. 52 (4):680-5. [QxMD MEDLINE Link].
Rivera M, Cortes R, Salvador A, et al. Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. Eur J Heart Fail. 2005 Dec. 7(7):1168-70. [QxMD MEDLINE Link].
Hermann-Arnhof KM, Hanusch-Enserer U, Kaestenbauer T, et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem. 2005 Jan. 51(1):138-43. [QxMD MEDLINE Link].
Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail. 2004 Mar 15. 6(3):295-300. [QxMD MEDLINE Link].
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000 Jul 27. 343(4):246-53. [QxMD MEDLINE Link].
Ezekowitz JA, Hernandez AF, Starling RC, et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). Am Heart J. 2009 Feb. 157(2):219-28. [QxMD MEDLINE Link].
Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999 Jul. 34(1):155-62. [QxMD MEDLINE Link].
Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002 Mar 6. 39(5):798-803. [QxMD MEDLINE Link].
Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC Jr, Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem. 2005 Mar. 51(3):569-77. [QxMD MEDLINE Link].
Fitzgerald RL, Cremo R, Gardetto N, et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J. 2005 Sep. 150(3):471-7. [QxMD MEDLINE Link].
Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992 Jan 9. 326(2):77-82. [QxMD MEDLINE Link].
Baig MK, Goldman JH, Caforio AL, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol. 1998 Jan. 31(1):195-201. [QxMD MEDLINE Link].
Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 1998 Jan. 31 (1):186-94. [QxMD MEDLINE Link].
McNally E, MacLeod H, Dellefave-Castillo L, et al. Arrhythmogenic right ventricular cardiomyopathy. GeneReviews. 1993. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation. 1997 Mar 18. 95(6):1686-744. [QxMD MEDLINE Link]. [Full Text].
Patel AR, Alsheikh-Ali AA, Mukherjee J, et al. 3D echocardiography to evaluate right atrial pressure in acutely decompensated heart failure correlation with invasive hemodynamics. JACC Cardiovasc Imaging. 2011 Sep. 4 (9):938-45. [QxMD MEDLINE Link].
Prior D, Coller J. Echocardiography in heart failure - a guide for general practice. Aust Fam Physician. 2010 Dec. 39(12):904-9. [QxMD MEDLINE Link].
Kirkpatrick JN, Wiegers SE, Lang RM. Left ventricular assist devices and other devices for end-stage heart failure: utility of echocardiography. Curr Cardiol Rep. 2010 May. 12(3):257-64. [QxMD MEDLINE Link].
Abraham J, Abraham TP. The role of echocardiography in hemodynamic assessment in heart failure. Heart Fail Clin. 2009 Apr. 5(2):191-208. [QxMD MEDLINE Link].
Gupta VA, Nanda NC, Sorrell VL. Role of echocardiography in the diagnostic assessment and etiology of heart failure in older adults: opacify, quantify, and rectify. Heart Fail Clin. 2017 Jul. 13(3):445-66. [QxMD MEDLINE Link].
Meersch M, Schmidt C, Zarbock A. Echophysiology: the transesophageal echo probe as a noninvasive Swan-Ganz catheter. Curr Opin Anaesthesiol. 2016 Feb. 29(1):36-45. [QxMD MEDLINE Link].
Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16. 343(20):1445-53. [QxMD MEDLINE Link].
[Guideline] Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol. 1995 Feb. 25(2):521-47. [QxMD MEDLINE Link].
Taillefer R, DePuey EG, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol. 1997 Jan. 29(1):69-77. [QxMD MEDLINE Link].
Bonow RO, Maurer G, Lee KL, et al, for the STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011 Apr 28. 364(17):1617-25. [QxMD MEDLINE Link].
Binanay C, Califf RM, Hasselblad V, et al, for the ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005 Oct 5. 294(13):1625-33. [QxMD MEDLINE Link].
[Guideline] Dickstein K, Vardas PE, Auricchio A, et al al for the Task Force on Acute Heart Failure of the European Society of Cardiology. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010 Nov. 31(21):2677-87. [QxMD MEDLINE Link]. [Full Text].
Bitter T, Westerheide N, Prinz C, et. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J. 2011 Jan. 32(1):61-74. [QxMD MEDLINE Link].
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4. 52(19):1527-39. [QxMD MEDLINE Link].
House AA, Haapio M, Lassus J, Bellomo R, Ronco C. Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis. 2010 Oct. 56(4):759-73. [QxMD MEDLINE Link].
Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail. 2010 Dec. 16(12):922-30. [QxMD MEDLINE Link].
Pleister AP, Baliga RR, Haas GJ. Acute study of clinical effectiveness of nesiritide in decompensated heart failure: nesiritide redux. Curr Heart Fail Rep. 2011 Sep. 8(3):226-32. [QxMD MEDLINE Link].
O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011 Jul 7. 365(1):32-43. [QxMD MEDLINE Link].
Konstam MA, Gheorghiade M, Burnett JC Jr, et al, for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28. 297(12):1319-31. [QxMD MEDLINE Link].
Massie BM, O'Connor CM, Metra M, et al, for the PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010 Oct 7. 363(15):1419-28. [QxMD MEDLINE Link].
Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011 Sep 6. 58(11):1152-61. [QxMD MEDLINE Link].
Roy D, Talajic M, Nattel S, et al, for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008 Jun 19. 358(25):2667-77. [QxMD MEDLINE Link].
Wilton SB, Fundytus A, Ghali WA, et al. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am J Cardiol. 2010 Nov 1. 106(9):1284-91. [QxMD MEDLINE Link].
MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011 May. 97(9):740-7. [QxMD MEDLINE Link].
Chen YM, Li ZB, Zhu M, Cao YM. Effects of exercise training on left ventricular remodelling in heart failure patients: an updated meta-analysis of randomised controlled trials. Int J Clin Pract. 2012 Aug. 66(8):782-91. [QxMD MEDLINE Link].
Mozaffarian D, Lemaitre RN, King IB, et al. Circulating long-chain omega-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med. 2011 Aug 2. 155(3):160-70. [QxMD MEDLINE Link].
Marchioli R, Levantesi G, Silletta MG, et al, for the GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. Expert Rev Cardiovasc Ther. 2009 Jul. 7 (7):735-48. [QxMD MEDLINE Link].
Armstrong PW, Pieske B, Anstrom KJ, et al, for the VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020 May 14. 382 (20):1883-93. [QxMD MEDLINE Link]. [Full Text].
Swedberg K, Komajda M, Böhm M, et al, for the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11. 376 (9744):875-85. [QxMD MEDLINE Link]. [Full Text].
Borer JS, Bohm M, Ford I, et al, for the SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012 Nov. 33 (22):2813-20. [QxMD MEDLINE Link]. [Full Text].
McMurray JJ, Packer M, Desai AS, et al, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11. 371 (11):993-1004. [QxMD MEDLINE Link]. [Full Text].
Solomon SD, McMurray JJV, Anand IS, et al, for the PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019 Oct 24. 381 (17):1609-20. [QxMD MEDLINE Link]. [Full Text].
Solomon SD, Zile M, Pieske B, et al, for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20. 380 (9851):1387-95. [QxMD MEDLINE Link].
Entresto (sacubitril/valsartan) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp. October 2019. Available at [Full Text].
Packer M, Anker SD, Butler J, et al, for the EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 Oct 8. 383 (15):1413-24. [QxMD MEDLINE Link]. [Full Text].
McMurray JJV, Solomon SD, Inzucchi SE, et al, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21. 381 (21):1995-2008. [QxMD MEDLINE Link]. [Full Text].
Anker SD, Butler J, Filippatos G, et al, for the EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14. 385 (16):1451-61. [QxMD MEDLINE Link].
Solomon SD, McMurray JJV, Claggett B, et al, for the DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 Sep 22. 387(12):1089-98. [QxMD MEDLINE Link]. [Full Text].
Bhatt DL, Szarek M, Steg PG, et al, for the SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021 Jan 14. 384(2):117-28. [QxMD MEDLINE Link]. [Full Text].
Bhatt DL, Szarek M, Pitt B, et al, for the SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021 Jan 14. 384(2):129-39. [QxMD MEDLINE Link]. [Full Text].
Massie BM, Collins JF, Ammon SE, et al, for the WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009 Mar 31. 119 (12):1616-24. [QxMD MEDLINE Link].
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013 Sep 1. 6 (5):525-33. [QxMD MEDLINE Link].
Konstantinou DM, Karvounis H, Giannakoulas G. Digoxin in heart failure with a reduced ejection fraction: a risk factor or a risk marker. Cardiology. 2016. 134 (3):311-9. [QxMD MEDLINE Link].
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20. 355 (3):251-9. [QxMD MEDLINE Link].
Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004 Feb 4. 43 (3):317-27. [QxMD MEDLINE Link].
Gheorghiade M, Abraham WT, Albert NM, et al, for the OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006 Nov 8. 296 (18):2217-26. [QxMD MEDLINE Link].
Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005 Dec 28. 294 (24):3124-30. [QxMD MEDLINE Link].
Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet. 2006 Apr 8. 367 (9517):1155-63. [QxMD MEDLINE Link].
Winck JC, Azevedo LF, Costa-Pereira A, Antonelli M, Wyatt JC. Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema--a systematic review and meta-analysis. Crit Care. 2006. 10 (2):R69. [QxMD MEDLINE Link]. [Full Text].
Vital FM, Saconato H, Ladeira MT, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev. 2008 Jul 16. CD005351. [QxMD MEDLINE Link].
Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009 Mar 17. 53 (11):905-18. [QxMD MEDLINE Link].
Gray A, Goodacre S, Newby DE, et al, for the 3CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008 Jul 10. 359 (2):142-51. [QxMD MEDLINE Link].
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4. 316 (23):1429-35. [QxMD MEDLINE Link].
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN, for the SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1. 325 (5):293-302. [QxMD MEDLINE Link].
Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28. 102 (22):2700-6. [QxMD MEDLINE Link].
Sodhi N, Lasala JM. Mechanical circulatory support in acute decompensated heart failure and shock. Interv Cardiol Clin. 2017 Jul. 6 (3):387-405. [QxMD MEDLINE Link].
Velazquez EJ, Lee KL, Jones RH, et al, for the STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016 Apr 21. 374(16):1511-20. [QxMD MEDLINE Link].
Busko M. Clevidipine shows promise for acute HF with high BP. Medscape Medical News from WebMD. February 10, 2014. Available at http://www.medscape.com/viewarticle/820377. Accessed: February 18, 2014.
Felker GM, Lee KL, Bull DA, et al, for the NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3. 364 (9):797-805. [QxMD MEDLINE Link].
Liu PP. Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol. 2008 Jul. 24 suppl B:25B-9B. [QxMD MEDLINE Link]. [Full Text].
Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999 Jan. 106 (1):90-6. [QxMD MEDLINE Link].
Neuberg GW, Miller AB, O'Connor CM, et al, for the PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002 Jul. 144 (1):31-8. [QxMD MEDLINE Link].
Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005 Dec 6. 46 (11):2047-51. [QxMD MEDLINE Link].
Young JB, Abraham WT, Stevenson LW, et al. Results of the VMAC Trial: vasodilation in the management of acute congestive heart failure. Circ. 2000 Nov 28. 102(22):a2794. [Full Text].
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002 Mar 27. 287 (12):1531-40. [QxMD MEDLINE Link].
Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis. Heart Fail Rev. 2012 Mar. 17 (2):313-24. [QxMD MEDLINE Link].
Costanzo MR, Guglin ME, Saltzberg MT, et al, for the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb 13. 49 (6):675-83. [QxMD MEDLINE Link].
CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994 Oct. 90 (4):1765-73. [QxMD MEDLINE Link].
Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010 Dec 9. 363 (24):2301-9. [QxMD MEDLINE Link].
Koehler F, Winkler S, Schieber M, et al, Telemedical Interventional Monitoring in Heart Failure Investigators. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation. 2011 May 3. 123 (17):1873-80. [QxMD MEDLINE Link].
P&T Community. FDA approves first implantable wireless device with remote monitoring to measure pulmonary artery pressure in certain heart failure patients (news release). Available at https://www.ptcommunity.com/news/20170422/fda-approves-first-implantable-device-remote-monitoring-measure-pa-pressure-heart. May 28, 2014; Accessed: June 2, 2014.
O'Riordan M. FDA approves first implantable device for remotely monitoring HF patients. Heartwire. Available at http://www.medscape.com/viewarticle/825805. May 28, 2014; Accessed: June 2, 2014.
Abraham WT, Adamson PB, Bourge RC, et al, for the CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011 Feb 19. 377 (9766):658-66. [QxMD MEDLINE Link].
Eisen HJ, Kobashigawa J, Keogh A, et al, for the Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005 May. 24 (5):517-25. [QxMD MEDLINE Link].
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, for the ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006 Jan 3. 47 (1):76-84. [QxMD MEDLINE Link].
Cardiac Rhythm News. FDA approves expanded indication for certain pacemakers and defibrillators used to treat heart failure. Available at https://cardiacrhythmnews.com/fda-approves-expanded-indication-for-certain-pacemakers-and-defibrillators-used-to-treat-heart-failure/. April 15, 2014; Accessed: April 15, 2014.
Stiles S. FDA approves Medtronic CRT sevices for mild HF with AV block. Medscape Medical News. Available at http://www.medscape.com/viewarticle/823485. April 10, 2014; Accessed: April 15, 2014.
Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation. 2009 Sep 8. 120 (10):835-42. [QxMD MEDLINE Link].
Santangelo G, Bursi F, Negroni MS, et al. Arrhythmic event prediction in patients with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown). 2021 Feb 1. 22 (2):110-7. [QxMD MEDLINE Link].
Ojo A, Tariq S, Harikrishnan P, Iwai S, Jacobson JT. Cardiac resynchronization therapy for heart failure. Interv Cardiol Clin. 2017 Jul. 6 (3):417-26. [QxMD MEDLINE Link].
Rosanio S, Schwarz ER, Ahmad M, et al. Benefits, unresolved questions, and technical issues of cardiac resynchronization therapy for heart failure. Am J Cardiol. 2005 Sep 1. 96 (5):710-7. [QxMD MEDLINE Link].
Tang AS, Wells GA, Talajic M, et al, for the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Dec 16. 363 (25):2385-95. [QxMD MEDLINE Link].
Giraldi F, Cattadori G, Roberto M, et al. Long-term effectiveness of cardiac resynchronization therapy in heart failure patients with unfavorable cardiac veins anatomy comparison of surgical versus hemodynamic procedure. J Am Coll Cardiol. 2011 Jul 26. 58 (5):483-90. [QxMD MEDLINE Link].
Abraham WT, Fisher WG, Smith AL, et al, for the MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002 Jun 13. 346 (24):1845-53. [QxMD MEDLINE Link].
Moss AJ, Hall WJ, Cannom DS, et al, for the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1. 361 (14):1329-38. [QxMD MEDLINE Link].
Arshad A, Moss AJ, Foster E, et al, for the MADIT-CRT Executive Committee. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011 Feb 15. 57 (7):813-20. [QxMD MEDLINE Link].
Ruwald MH, Ruwald AC, Jons C, et al. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol. 2013 Apr 9. 61 (14):1518-26. [QxMD MEDLINE Link].
Cleland JG, Daubert JC, Erdmann E, et al, for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14. 352 (15):1539-49. [QxMD MEDLINE Link].
Bristow MR, Saxon LA, Boehmer J, et al, for the Comparison of Medical Therapy, Pacing, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20. 350 (21):2140-50. [QxMD MEDLINE Link].
Curtis AB, Worley SJ, Adamson PB, et al, for the Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013 Apr 25. 368 (17):1585-93. [QxMD MEDLINE Link].
Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med. 1984 Nov 22. 311 (21):1333-9. [QxMD MEDLINE Link].
VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation. 1992 Jul. 86 (1):121-30. [QxMD MEDLINE Link].
Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation. 1995 May 1. 91 (9):2335-44. [QxMD MEDLINE Link].
Robinson TN, Morrell TD, Pomerantz BJ, Heimbach JK, Cairns CB, Harken AH. Therapeutically accessible clinical cardiac states. J Am Coll Surg. 2000 Oct. 191 (4):452-63. [QxMD MEDLINE Link].
Senior R, Lahiri A, Kaul S. Effect of revascularization on left ventricular remodeling in patients with heart failure from severe chronic ischemic left ventricular dysfunction. Am J Cardiol. 2001 Sep 15. 88 (6):624-9. [QxMD MEDLINE Link].
Velazquez EJ, Lee KL, Deja MA, et al, for the STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011 Apr 28. 364 (17):1607-16. [QxMD MEDLINE Link]. [Full Text].
Elefteriades JA, Morales DL, Gradel C, Tollis G Jr, Levi E, Zaret BL. Results of coronary artery bypass grafting by a single surgeon in patients with left ventricular ejection fractions < or = 30%. Am J Cardiol. 1997 Jun 15. 79 (12):1573-8. [QxMD MEDLINE Link].
Kron IL, Flanagan TL, Blackbourne LH, Schroeder RA, Nolan SP. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg. 1989 Sep. 210 (3):348-52; discussion 352-4. [QxMD MEDLINE Link]. [Full Text].
Doenst T, Velazquez EJ, Beyersdorf F, et al, for the STICH investigators. To STICH or not to STICH: we know the answer, but do we understand the question?. J Thorac Cardiovasc Surg. 2005 Feb. 129 (2):246-9. [QxMD MEDLINE Link].
Joyce D, Loebe M, Noon GP, et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol. 2003 Nov. 18 (6):454-7. [QxMD MEDLINE Link].
Sharoni E, Song HK, Peterson RJ, Guyton RA, Puskas JD. Off pump coronary artery bypass surgery for significant left ventricular dysfunction: safety, feasibility, and trends in methodology over time--an early experience. Heart. 2006 Apr. 92 (4):499-502. [QxMD MEDLINE Link]. [Full Text].
Calafiore AM, Di Giammarco G, Teodori G, et al. Late results of first myocardial revascularization in multiple vessel disease: single versus bilateral internal mammary artery with or without saphenous vein grafts. Eur J Cardiothorac Surg. 2004 Sep. 26 (3):542-8. [QxMD MEDLINE Link].
Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano ST, Holmes DR Jr. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. Circulation. 2002 Aug 13. 106 (7):809-13. [QxMD MEDLINE Link].
Carabello BA. Clinical practice. Aortic stenosis. N Engl J Med. 2002 Feb 28. 346 (9):677-82. [QxMD MEDLINE Link].
Lindblom D, Lindblom U, Qvist J, Lundstrom H. Long-term relative survival rates after heart valve replacement. J Am Coll Cardiol. 1990 Mar 1. 15(3):566-73. [QxMD MEDLINE Link].
Connolly HM, Oh JK, Schaff HV, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction:result of aortic valve replacement in 52 patients. Circulation. 2000 Apr 25. 101 (16):1940-6. [QxMD MEDLINE Link].
deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol. 1995 Jan 15. 75 (2):191-4. [QxMD MEDLINE Link].
Vaquette B, Corbineau H, Laurent M, et al. Valve replacement in patients with critical aortic stenosis and depressed left ventricular function: predictors of operative risk, left ventricular function recovery, and long term outcome. Heart. 2005 Oct. 91 (10):1324-9. [QxMD MEDLINE Link]. [Full Text].
Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation. 1999 Apr 13. 99 (14):1851-7. [QxMD MEDLINE Link].
Chaliki HP, Mohty D, Avierinos JF, et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation. 2002 Nov 19. 106 (21):2687-93. [QxMD MEDLINE Link].
Enriquez-Sarano M, Tajik AJ. Clinical practice. Aortic regurgitation. N Engl J Med. 2004 Oct 7. 351 (15):1539-46. [QxMD MEDLINE Link].
Lancellotti P, Gerard PL, Pierard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J. 2005 Aug. 26 (15):1528-32. [QxMD MEDLINE Link].
Patel JB, Borgeson DD, Barnes ME, Rihal CS, Daly RC, Redfield MM. Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail. 2004 Aug. 10 (4):285-91. [QxMD MEDLINE Link].
Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg. 1998 Feb. 115 (2):381-6; discussion 387-8. [QxMD MEDLINE Link].
Akasaka T, Yoshida K, Hozumi T, et al. Restricted coronary flow reserve in patients with mitral regurgitation improves after mitral reconstructive surgery. J Am Coll Cardiol. 1998 Dec. 32 (7):1923-30. [QxMD MEDLINE Link].
Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005 Feb 1. 45 (3):381-7. [QxMD MEDLINE Link].
McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2004 Dec. 128 (6):916-24. [QxMD MEDLINE Link].
Srichai MB, Grimm RA, Stillman AE, et al. Ischemic mitral regurgitation: impact of the left ventricle and mitral valve in patients with left ventricular systolic dysfunction. Ann Thorac Surg. 2005 Jul. 80 (1):170-8. [QxMD MEDLINE Link].
Morishita A, Shimakura T, Nonoyama M, Takasaki T. Mitral valve replacement in ischemic mitral regurgitation. Preservation of both anterior and posterior mitral leaflets. J Cardiovasc Surg (Torino). 2002 Apr. 43 (2):147-52. [QxMD MEDLINE Link].
Yun KL, Sintek CF, Miller DC, et al. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg. 2002 Apr. 123 (4):707-14. [QxMD MEDLINE Link].
Gillinov AM, Wierup PN, Blackstone EH, et al. Is repair preferable to replacement for ischemic mitral regurgitation?. J Thorac Cardiovasc Surg. 2001 Dec. 122 (6):1125-41. [QxMD MEDLINE Link].
Miller DC. Ischemic mitral regurgitation redux--to repair or to replace?. J Thorac Cardiovasc Surg. 2001 Dec. 122 (6):1059-62. [QxMD MEDLINE Link].
Orban M, Hausleiter J. Edge-to-edge mitral valve repair: solid data and a prosperous future. Heart. 2018 Feb. 104(4):280-1. [QxMD MEDLINE Link].
Vahanian A, Urena M, Ince H, Nickenig G. Mitral valve: repair/clips/cinching/chordae. EuroIntervention. 2017 Sep 24. 13 (AA):AA22-30. [QxMD MEDLINE Link].
Feldman T, Kar S, Rinaldi M, et al, for the EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009 Aug 18. 54 (8):686-94. [QxMD MEDLINE Link].
Chiarito M, Pagnesi M, Martino EA, et al. Outcome after percutaneous edge-to-edge mitral repair for functional and degenerative mitral regurgitation: a systematic review and meta-analysis. Heart. 2018 Feb. 104(4):306-12. [QxMD MEDLINE Link].
Geis NA, Puls M, Lubos E, et al. Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2018 Mar. 20(3):598-608. [QxMD MEDLINE Link].
Buckberg GD. Ventricular restoration--a surgical approach to reverse ventricular remodeling. Heart Fail Rev. 2004 Oct. 9 (4):233-9; discussion 347-51. [QxMD MEDLINE Link].
Yamaguchi A, Ino T, Adachi H, et al. Left ventricular volume predicts postoperative course in patients with ischemic cardiomyopathy. Ann Thorac Surg. 1998 Feb. 65 (2):434-8. [QxMD MEDLINE Link].
Mickleborough LL, Carson S, Ivanov J. Repair of dyskinetic or akinetic left ventricular aneurysm: results obtained with a modified linear closure. J Thorac Cardiovasc Surg. 2001 Apr. 121 (4):675-82. [QxMD MEDLINE Link].
Ott DA, Parravacini R, Cooley DA, et al. Improved cardiac function following left ventricular aneurysm resection: pre- and postoperative performance studies in 150 patients. Tex Heart Inst J. 1982 Sep. 9 (3):267-73. [QxMD MEDLINE Link]. [Full Text].
Athanasuleas CL, Buckberg GD, Stanley AW, et al, for the RESTORE group. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol. 2004 Oct 6. 44 (7):1439-45. [QxMD MEDLINE Link].
Jones RH, Velazquez EJ, Michler RE, et al, for the STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009 Apr 23. 360 (17):1705-17. [QxMD MEDLINE Link]. [Full Text].
Imamura T, Chung B, Nguyen A, Sayer G, Uriel N. Clinical implications of hemodynamic assessment during left ventricular assist device therapy. J Cardiol. 2018 Apr. 71 (4):352-8. [QxMD MEDLINE Link].
Timms D. A review of clinical ventricular assist devices. Med Eng Phys. 2011 Nov. 33 (9):1041-7. [QxMD MEDLINE Link].
Pamboukian SV, Tallaj JA, Brown RN, et al. Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol. J Heart Lung Transplant. 2011 Aug. 30 (8):879-87. [QxMD MEDLINE Link].
Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007 Jul 31. 116 (5):497-505. [QxMD MEDLINE Link].
Daneshmand MA, Rajagopal K, Lima B, et al. Left ventricular assist device destination therapy versus extended criteria cardiac transplant. Ann Thorac Surg. 2010 Apr. 89 (4):1205-9; discussion 1210. [QxMD MEDLINE Link].
US Food and Drug Administration. Recently-approved devices: HeartWare HVAD - P100047/S090. Available at https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm581473.htm. September 27, 2017 [Updated October 31, 2017]; Accessed: October 31, 2017.
US National Library of Medicine. Evaluation of the Jarvik 2000 Left Ventricular Assist System with post-auricular connector--destination therapy study. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT01627821. Updated: October 16, 2017; Accessed: October 31, 2017.
Rose EA, Gelijns AC, Moskowitz AJ, et al, for theRandomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001 Nov 15. 345 (20):1435-43. [QxMD MEDLINE Link].
Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg. 2005 Jan. 129 (1):9-17. [QxMD MEDLINE Link].
Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011 May 10. 57 (19):1890-8. [QxMD MEDLINE Link].
Ventura PA, Alharethi R, Budge D, et al. Differential impact on post-transplant outcomes between pulsatile- and continuous-flow left ventricular assist devices. Clin Transplant. 2011 Jul-Aug. 25 (4):E390-5. [QxMD MEDLINE Link].
Slaughter MS, Pagani FD, Rogers JG, et al, for the HeartMate II Clinical Investigators. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010 Apr. 29 (4 suppl):S1-39. [QxMD MEDLINE Link].
Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant. 2011 Feb. 30 (2):115-23. [QxMD MEDLINE Link].
Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005. J Heart Lung Transplant. 2005 Aug. 24 (8):945-55. [QxMD MEDLINE Link].
Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: eighth official pediatric report--2005. J Heart Lung Transplant. 2005 Aug. 24(8):968-82. [QxMD MEDLINE Link].
United Network for Organ Sharing (US). National data. UNOS. Available at https://unos.org/data/. October 24, 2017; Accessed: November 1, 2017.
Stevenson LW, Kormos RL, Bourge RC, et al. Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland. J Am Coll Cardiol. 2001 Jan. 37 (1):340-70. [QxMD MEDLINE Link].
Gray NA Jr, Selzman CH. Current status of the total artificial heart. Am Heart J. 2006 Jul. 152 (1):4-10. [QxMD MEDLINE Link].
Cooley DA, Liotta D, Hallman GL, Bloodwell RD, Leachman RD, Milam JD. Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol. 1969 Nov. 24 (5):723-30. [QxMD MEDLINE Link].
Platis A, Larson DF. CardioWest temporary total artificial heart. Perfusion. 2009 Sep. 24 (5):341-6. [QxMD MEDLINE Link].
Roussel JC, Senage T, Baron O, et al. CardioWest (Jarvik) total artificial heart: a single-center experience with 42 patients. Ann Thorac Surg. 2009 Jan. 87 (1):124-9; discussion 130. [QxMD MEDLINE Link].
Anderson E, Jaroszewski D, Pierce C, DeValeria P, Arabia F. Parallel application of extracorporeal membrane oxygenation and the CardioWest total artificial heart as a bridge to transplant. Ann Thorac Surg. 2009 Nov. 88 (5):1676-8. [QxMD MEDLINE Link].
Morris RJ. Total artificial heart--concepts and clinical use. Semin Thorac Cardiovasc Surg. 2008 Fall. 20 (3):247-54. [QxMD MEDLINE Link].
Meyer A, Slaughter M. The total artificial heart. Panminerva Med. 2011 Sep. 53 (3):141-54. [QxMD MEDLINE Link].
US National Library of Medicine. European clinical evaluation of the Carmat total artificial heart (advance HF). ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT02962973. Updated: November 25, 2016; Accessed: November 1, 2017.
[Guideline] Ackerman MJ, Priori SG, Willems S, et al, Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011 Aug. 13 (8):1077-109. [QxMD MEDLINE Link]. [Full Text].
Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010 Apr. 31 (7):806-14. [QxMD MEDLINE Link]. [Full Text].
[Guideline] O'Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol. 2020 Feb. 36 (2):159-69. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Tracy CM, Epstein AE, Darbar D,et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation. 2012 Oct 2. 126 (14):1784-800. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015 Nov 1. 36 (41):2793-867. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Rihal CS, Naidu SS, Givertz MM, et al, Society for Cardiovascular Angiography and Interventions (SCAI), Heart Failure Society of America (HFSA), et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Association, the Cardiological Society of India, & Sociedad Latino Americana de Cardiologia Intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. J Am Coll Cardiol. 2015 May 19. 65 (19):e7-e26. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Feldman D, Pamboukian SV, Teuteberg JJ, et al., International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013 Feb. 32 (2):157-87. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012 Nov 27. 126 (22):2648-67. [QxMD MEDLINE Link]. [Full Text].
Masini M, Elia E, Vianello PF, et al. Frequency, predictors and prognostic impact of implantable cardioverter defibrillator shocks in a primary prevention population with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown). 2021 Feb 1. 22 (2):118-25. [QxMD MEDLINE Link].
Lloyd-Jones D, Adams RJ, Brown TM, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23. 121 (7):948-54. [QxMD MEDLINE Link].

Media Gallery

Heart Failure. This chest radiograph shows an enlarged cardiac silhouette and edema at the lung bases, signs of acute heart failure.
Heart Failure. Cardiac cirrhosis. Congestive hepatopathy with large renal vein.
Heart Failure. Cardiac cirrhosis. Congestive hepatopathy with large inferior vena cava.
Heart Failure. This electrocardiogram (ECG) is from a 32-year-old female with recent-onset congestive heart failure and syncope. The ECG demonstrates a tachycardia with a 1:1 atrial:ventricular relationship. It is not clear from this tracing whether the atria are driving the ventricles (sinus tachycardia) or the ventricles are driving the atria (ventricular tachycardia [VT]). At first glance, sinus tachycardia in this ECG might be considered with severe conduction disease manifesting as marked first-degree atrioventricular block with left bundle branch block. On closer examination, the ECG morphology gives clues to the actual diagnosis of VT. These clues include the absence of RS complexes in the precordial leads, a QS pattern in V6, and an R wave in aVR. The patient proved to have an incessant VT associated with dilated cardiomyopathy.
Heart Failure. This is a posteroanterior view of a right ventricular endocardial activation map during ventricular tachycardia in a patient with a previous septal myocardial infarction. The earliest activation is recorded in red; late activation displays as blue to magenta. Fragmented low-amplitude diastolic local electrocardiograms were recorded adjacent to the earliest (red) breakout area, and local ablation in this scarred zone (red dots) resulted in termination and noninducibility of this previously incessant arrhythmia.
Heart Failure. A 28-year-old woman presented with acute heart failure secondary to chronic hypertension. The enlarged cardiac silhouette on this anteroposterior (AP) radiograph is caused by acute heart failure due to the effects of chronic high blood pressure on the left ventricle. The heart then becomes enlarged, and fluid accumulates in the lungs (ie, pulmonary congestion).
Heart Failure. Epsilon wave on an electrocardiogram in a patient with arrhythmogenic right ventricular dysplasia (ARVD). ARVD is a congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the RV wall and loss of myocardial cells. Primary injuries usually are at the free wall of the RV and right atria, resulting in ventricular and supraventricular arrhythmias. The most significant of all rhythms associated with heart failure are the life-threatening ventricular arrhythmias.
Heart Failure. Electrocardiogram depicting ventricular fibrillation in a patient with a left ventricular assist device (LVAD). Ventricular fibrillation is often due to ischemic heart disease and can lead to myocardial infarction and/or sudden death.
Heart Failure. The rhythm on this electrocardiogram (ECG) is sinus with borderline PR prolongation. There is evidence of an acute/evolving anterior ischemia/myocardial infarction (MI) superimposed on the left bundle branch block (LBBB)–like pattern. Note the primary T-wave inversions in leads V2-V4, rather than the expected discordant (upright) T waves in the leads with a negative QRS. Although this finding is not particularly sensitive for ischemia/MI with LBBB, such primary T-wave changes are relatively specific. The prominent voltage with left atrial abnormality and leftward axis in concert with the left ventricular intraventricular conduction delay (IVCD) are consistent with underlying left ventricular hypertrophy. This ECG is an example of "bundle branch block plus." Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. This electrocardiogram (ECG) shows evidence of severe left ventricular hypertrophy (LVH) with prominent precordial voltage, left atrial abnormality, lateral ST-T abnormalities, and a somewhat leftward QRS axis (–15º). The patient had malignant hypertension with acute heart failure, accounting also for the sinus tachycardia (blood pressure initially 280/180 mmHg). The ST-T changes seen here are nonspecific and could be due to, for example, LVH alone or coronary artery disease. However, the ECG is not consistent with extensive inferolateral myocardial infarction. Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. The rhythm on this electrocardiogram is atrial tachycardia (rate, 154 beats/min) with a 2:1 atrioventricular (AV) block. Note the partially hidden, nonconducted P waves on the ST segments (eg, leads I and aVL). The QRS is very wide with an atypical intraventricular conduction defect (IVCD) pattern. The rSR' type complex in the lateral leads (I, aVL) is not due to a right bundle branch block (RBBB) but to an atypical left ventricular conduction defect. These unexpected rSR' complexes in the lateral leads (El-Sherif sign) correlate with underlying extensive myocardial infarction (MI) and, occasionally, ventricular aneurysm. (El-Sherif. Br Heart J. 1970;32:440-8.) The notching on the upstroke of the S waves in lead V4 with a left bundle branch block-type pattern also suggests underlying MI (Cabrera sign). This patient had severe cardiomyopathy secondary to coronary artery disease, with extensive left ventricular wall motion abnormalities. Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. On this electrocardiogram, baseline artifact is present, simulating atrial fibrillation. Such artifact may be caused by a variety of factors, including poor electrode contact, muscle tremor, and electrical interference. A single premature ventricular complex (PVC) is present with a compensatory pause such that the RR interval surrounding the PVC is twice as long as the preceding sinus RR interval. Evidence of a previous anterior myocardial infarction is present with pathologic Q waves in leads V1-V3. Borderline-low precordial voltage is a nonspecific finding. Cardiac catheterization showed a 90% stenosis in the patient's proximal portion the left anterior descending coronary artery, which was treated with angioplasty and stenting. Broad P waves in lead V1 with a prominent negative component is consistent with a left atrial abnormality. Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. This electrocardiogram (ECG) is from a patient who underwent urgent cardiac catheterization, which revealed diffuse severe coronary spasm (most marked in the left circumflex system) without any fixed obstructive lesions. Severe left ventricular wall motion abnormalities were present, involving the anterior and inferior segments. A question of so-called takotsubo cardiomyopathy (left ventricular apical ballooning syndrome) is also raised (see Bybee et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Int Med 2004:141:858-65). The latter is most often reported in postmenopausal, middle-aged to elderly women in the context of acute emotional stress and may cause ST elevations acutely with subsequent T-wave inversions. A cocaine-induced cardiomyopathy (possibly related to coronary vasospasm) is a consideration but was excluded here. Myocarditis may also be associated with this type of ECG and the cardiomyopathic findings shown here. No fixed obstructive epicardial coronary lesions were detected by coronary arteriography. The findings in this ECG include low-amplitude QRS complexes in the limb leads (with an indeterminate QRS axis), loss of normal precordial R-wave progression (leads V1-V3), and prominent anterior/lateral T-wave inversions. Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. This electrocardiogram shows an extensive acute/evolving anterolateral myocardial infarction pattern, with ST-T changes most apparent in leads V2-V6, I, and aVL. Slow R-wave progression is also present in leads V1-V3. The rhythm is borderline sinus tachycardia with a single premature atrial complex (PAC) (fourth beat). Note also the low limb-lead voltage and probable left atrial abnormality. Left ventriculography showed diffuse hypokinesis as well as akinesis of the anterolateral and apical walls, with an ejection fraction estimated at 33%. Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. This electrocardiogram shows a patient is having an evolving anteroseptal myocardial infarction secondary to cocaine. There are Q waves in leads V2-V3 with ST-segment elevation in leads V2-V5 associated with T-wave inversion. Also noted are biphasic T waves in the inferior leads. These multiple abnormalities suggest occlusion of a large left anterior descending artery that wraps around the apex of the heart (or multivessel coronary artery disease). Image courtesy of http://ecg.bidmc.harvard.edu.
Heart Failure. A color-enhanced angiogram of the left heart shows a plaque-induced obstruction (top center) in a major artery, which can lead to myocardial infarction (MI). MIs can precipitate heart failure.
Heart Failure. Emphysema is included in the differential diagnosis of heart failure. In this radiograph, emphysema bubbles are noted in the left lung; these can severely impede breathing capacity.
Heart Failure. Cervicocephalic fibromuscular dysplasia (FMD) can lead to complications such as hypertension and chronic kidney failure, which can lead to heart failure. In this color Doppler and spectral Doppler ultrasonographic examination of the left internal carotid artery (ICA) in a patient with cervicocephalic FMD, stenoses of about 70% is seen in the ICA.
Heart Failure. Cervicocephalic fibromuscular dysplasia (FMD) can lead to complications such as hypertension and chronic kidney failure, which, in turn, can lead to heart failure. Nodularity in an artery is known as the "string-of-beads sign," and it can be seen this color Doppler ultrasonographic image from a 51-year-old patient with low-grade stenosing FMD of the internal carotid artery (ICA).
Heart Failure. Electrocardiogram from a 46-year-old man with long-standing hypertension. Note the left atrial abnormality and left ventricular hypertrophy with strain.
Heart Failure. Electrocardiogram from a 46-year-old man with long-standing hypertension. Left atrial abnormality and left ventricular hypertrophy with strain is revealed.
Heart Failure. Apical four-chamber echocardiogram in a 37-year-old man with arrhythmogenic right ventricular dysplasia (ARVD), a congenital cardiomyopathy. Note the prominent trabeculae and abnormal wall motion of the dilated RV. ARVD can result in ventricular and supraventricular arrhythmias. The most significant of all rhythms associated with heart failure are the life-threatening ventricular arrhythmias.
Heart Failure. Cardiac magnetic resonance image (CMRI), short-axis view. This image shows right ventricular (RV) dilatation, trabucular derangement, aneurysm formation, and dyskinetic free wall in a patient with arrhythmogenic RV dysplasia.
Heart Failure. This transthoracic echocardiogram demonstrates severe mitral regurgitation with a heavily calcified mitral valve and prolapse of the posterior leaflet into the left atrium.
Heart Failure. Echocardiogram of a patient with severe pulmonic stenosis. This image shows a parasternal short-axis view of a thickened pulmonary valve. Pulmonic stenosis can lead to pulmonary hypertension, which can result in hepatic congestion and in right-sided heart failure.
Heart Failure. Echocardiogram of a patient with severe pulmonic stenosis. This image shows a Doppler scan of the peak velocity (5.2 m/s) and gradients (peak 109 mmHg, mean 65 mmHg) across the valve.
Heart Failure. Echocardiogram of a patient with severe pulmonic stenosis. This image shows moderately severe pulmonary insufficiency (orange color flow) is also present.
Heart Failure. This video is an echocardiogram of a patient with severe pulmonic stenosis. The first segment shows the parasternal short-axis view of the thickened pulmonary valve. The second segment shows the presence of moderate pulmonary insufficiency (orange color flow). AV = aortic valve, PA = pulmonary artery, PI = pulmonary insufficiency, PV = pulmonary valve.
Heart Failure. Transesophageal echocardiogram with continuous wave Doppler interrogation across the mitral valve. An increased mean gradient of 16 mmHg is revealed, consistent with severe mitral stenosis.

of 29

Table 1. Framingham Diagnostic Criteria for Heart Failure

Major Criteria	Minor Criteria
Paroxysmal nocturnal dyspnea	Nocturnal cough
Weight loss of 4.5 kg in 5 days in response to treatment	Dyspnea on ordinary exertion
Neck vein distention	A decrease in vital capacity by one third the maximal value recorded
Rales	Pleural effusion
Acute pulmonary edema	Tachycardia (rate of 120 bpm)
Hepatojugular reflux	Hepatomegaly
S₃ gallop	Bilateral ankle edema
Central venous pressure >16 cm water
Circulation time of ≥25 seconds
Radiographic cardiomegaly
Pulmonary edema, visceral congestion, or cardiomegaly at autopsy
Source: Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol.

Table 2. Evidence-Based BNP and NT-proBNP Cutoff Values for Diagnosing HF

Criterion		BNP, pg/mL		NT-proBNP, pg/mL
Criterion		HF Unlikely (LR-Negative)	HF Likely (LR-Positive)	HF Unlikely (LR-Negative)	HF Likely (LR-Positive)
Age, y	>17	< 100 (0.13)^*	>500 (8.1)^*	-	-
	>21	-	-	< 300 (0.02)^†	-
	21-50	-	-	-	>450 (14)^†
	50-75	-	-	-	>900 (5.0)^†
	>75	-	-	-	>1800 (3.1)^†
Estimated GFR, < 60 mL/min		< 200 (0.13)^‡	>500 (9.3)^‡	-	-
BNP = B-type natriuretic peptide; GRF = glomerular filtration rate; HF = heart failure; LR = likelihood ratio; NPV = negative predictive value; NT-pro-BNP = N-terminal proBNP; PPV = positive predictive value; – = not specifically defined. ^* Derived from Breathing Not Properly data (1586 emergency department [ED] patients, prevalence of HF = 47%).^[65] ^† Derived from PRIDE data (1256 ED patients, prevalence of HF = 57%).^{[66, 75]} ^‡ Derived from subset of Breathing Not Properly data (452 ED patients, prevalence of HF = 49%).^[74]

Table 3. 2013 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Heart Failure Staging System

Stage	Description	Examples	Notes
A	At high risk for heart failure but without structural heart disease or symptoms of heart failure	Patients with coronary artery disease, hypertension, or diabetes mellitus without impaired left ventricular (LV) function, LV hypertrophy (LVH), or geometric chamber distortion	Patients with predisposing risk factors for developing heart failure No corresponding New York Heart Association (NYHA) functional classification
B	Structural heart disease but without signs/symptoms of heart failure	Patients who are asymptomatic but who have LVH and/or impaired LV function	Corresponds with patients with NYHA class I
C	Structural heart disease with current or past symptoms of heart failure	Patients with known structural heart disease and shortness of breath and fatigue, as well as reduced exercise tolerance	The majority of patients with heart failure are in this stage Corresponds with NYHA classes I, II, III and IV
D	Refractory heart failure requiring specialized interventions	Patients who have marked symptoms at rest despite maximal medical therapy	Patients in this stage may be eligible to receive mechanical circulatory support, receive continuous inotropic infusions, undergo procedures to facilitate fluid removal, or undergo heart transplantation or other procedures Corresponds with patients with NYHA class IV

Table 4. 2022 ACC/AHA/Heart Failure Society of America (HFSA) Heart Failure Staging System

Proposed Terminology	Stage	Definition and Criteria
At risk for HF	A	At risk of HF; asymptomatic, no structural heart disease nor cardiac biomarkers of stretch injury (eg, patients with hypertension, atherosclerotic cardiovascular disease, diabetes, metabolic syndrome and obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or positive family history of cardiomyopathy)
Pre-HF	B	No signs/symptoms of HF and evidence of one of the following: Structural heart disease Reduced left or right ventricular systolic function Reduced ejection fraction, reduced strain Ventricular hypertrophy Enlarged chamber Wall motion anomalies Valvular heart disease Evidence for raised filling pressures by invasive hemodynamic measurements or by noninvasive imaging that suggests elevated filling pressures (eg, Doppler echocardiography) Patients with risk factors and raised levels of B-type natriuretic peptides or persistently elevated cardiac troponin in the absence of competing diagnoses that result in such biomarker elevations (eg, acute coronary syndrome, chronic kidney disease, pulmonary embolus, or myopericarditis)
Symptomatic HF	C	Structural heart disease with current or previous symptoms of HF
Advanced HF	D	Marked HF symptoms that interfere with daily life and with repeated hospitalizations despite attempts to optimize guideline-directed medical therapy
HF = heart failure

Table 5. 2022 ACC/AHA/HFSA Classification of Heart Failure (HF) by Left Ventricular Ejection Fraction (LVEF)

HF Type by LVEF

Criteria

HF with reduced EF

(HFrEF)

LVEF ≤40%

HF with improved EF

(HFimpEF)

Previous LVEF ≤40% and a followup LVEF >40%

HF with mildly reduced EF

(HFmrEF)

LVEF of 41%-49%

Evidence of spontaneous/provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)

HF with preserved EF

(HFpEF)

LVEF ≥50%

Evidence of spontaneous/provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)

Back to List

Author

Ioana Dumitru, MD Associate Professor of Medicine, Division of Cardiology, Founder and Medical Director, Heart Failure and Cardiac Transplant Program, University of Nebraska Medical Center; Associate Professor of Medicine, Division of Cardiology, Veterans Affairs Medical Center

Ioana Dumitru, MD is a member of the following medical societies: American College of Cardiology, Heart Failure Society of America, International Society for Heart and Lung Transplantation

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Yasmine S Ali, MD, MSCI, FACC, FACP Assistant Clinical Professor of Medicine, Vanderbilt University School of Medicine; President, LastSky Writing, LLC

Yasmine S Ali, MD, MSCI, FACC, FACP is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, American Medical Writers Association, National Lipid Association, Tennessee Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: LastSky Writing;Philips Healthcare;M Health;Verywell Health; MedStudy;WellnessVerge;Prose Media; AKH, Inc.; LearnRoll, LLC; Eradigm; RxCe.com; M3 USA; M3 EU; Future US Inc.; Edanz Group; ChesterPA511<br/>Serve(d) as a speaker or a member of a speakers bureau for: RxCe.com.

Chief Editor

Gyanendra K Sharma, MD, FACC, FASE Professor of Medicine and Radiology, Director, Adult Echocardiography Laboratory, Section of Cardiology, Medical College of Georgia at Augusta University

Gyanendra K Sharma, MD, FACC, FASE is a member of the following medical societies: American Association of Cardiologists of Indian Origin, American Association of Physicians of Indian Origin, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography

Disclosure: Nothing to disclose.

Additional Contributors

Mathue M Baker, MD Cardiologist, BryanLGH Heart Institute and Saint Elizabeth Regional Medical Center

Mathue M Baker, MD is a member of the following medical societies: American College of Cardiology

Disclosure: Nothing to disclose.

Henry H Ooi, MD, MRCPI Director, Advanced Heart Failure and Cardiac Transplant Program, Nashville Veterans Affairs Medical Center; Assistant Professor of Medicine, Vanderbilt University School of Medicine

Disclosure: Nothing to disclose.

Mariclaire Cloutier Freelance editor, Medscape Drugs & Diseases

Disclosure: Nothing to disclose.

Acknowledgements

Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York AcademyofSciences,and Society for Academic Emergency Medicine